Lab901 and Biofortuna to collaborate on automated PCR Dx for HLA and Coeliac disease

17-Nov-2009 - United Kingdom

Lab901 and Biofortuna announced that they will collaborate on the launch of an automated PCR Dx system for the rapid detection of certain HLA-related diseases such as coeliac disease. Lab901 will be optimising its automated ScreenTape® PCR diagnostics platform for use with Biofortuna’s range of multiplex PCR diagnostics kits for the detection of Coeliac disease, and other HLA related disease such as reactive arthritis, diabetes and drug hypersensitivity.

Dr Mike Bunce, Biofortuna’s CEO said “We are very excited about the launch of our first line of kits for Coeliac disease susceptibility and Abacavir hypersensitivity. Biofortuna’s blend of easy-to-use one-step PCR technology and multiplexing capability means we are confident of quickly taking market share. Having evaluated several automated systems, we have chosen to work with Lab901 because of the ease-of-use, cost-effectiveness and reproducibility of the ScreenTape platform".

Financial terms were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy

See the theme worlds for related content